CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- FinancialsLow earnings quality
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.91BUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.7640xvs all stocks
52-Week Change
202.83%vs all stocks
Market Capitalization
1.91BUSDvs all stocks (USD)
Enterprise Value
1.53BUSDvs all stocks (USD)
Forward P/E
-11.40xvs Biotechnology peers
Price to Book (MRQ)
6.66xvs Biotechnology peers
Enterprise to EBITDA
-10.77xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-23.64%vs Biotechnology peers
Return on Equity (TTM)
-36.87%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 19, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-142.37MUSDvs all stocks (USD)
Net Income (TTM)
-131.10MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-102.25MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-60.14MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-132.76MUSDvs all stocks (USD)
Pre-tax Income
-119.95MUSDFY2025 · Dec 31, 2025Net Income
-119.95MUSDFY2025 · Dec 31, 2025EBIT
-132.76MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-132.22MUSDFY2025 · Dec 31, 2025Research & Development
102.93MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
29.83MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
12.81MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-119.95MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-91.31MUSDFY2025 · Dec 31, 2025Free Cash Flow
-91.45MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
78.39MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-119.95MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
546.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
28.01MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
83.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-141.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-101.25MUSDFY2025 · Dec 31, 2025Sale of Investments
173.86MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
72.46MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
0.00USDFY2025 · Dec 31, 2025Net Financing Cash Flow
0.00USDFY2025 · Dec 31, 2025Shares Outstanding
59.47MSharesUpdated Jul 19, 2026Float Shares
30.88MSharesUpdated Jul 19, 2026Shares Short
11.92MSharesUpdated Jul 19, 2026Short Ratio
10.11daysvs all stocks
Short % of Shares Outstanding
37.07%vs all stocks
% Held by Insiders
2.86%vs all stocks
% Held by Institutions
111.66%vs all stocks
Total Cash (MRQ)
383.47MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
6.45USDUpdated Jul 19, 2026Total Debt (MRQ)
5.70MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0147xvs Biotechnology peers
Current Ratio (MRQ)
20.49xvs Biotechnology peers
Book Value per Share (MRQ)
4.83USDUpdated Jul 19, 2026Total Assets
282.61MUSDvs all stocks (USD)
Total Current Assets
265.45MUSDFY2025 · Dec 31, 2025Total Liabilities
23.43MUSDFY2025 · Dec 31, 2025Total Non-current Assets
17.16MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
5.34MUSDFY2025 · Dec 31, 2025Total Current Liabilities
18.09MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
77.39MUSDFY2025 · Dec 31, 2025Other Short-term Investments
178.62MUSDFY2025 · Dec 31, 2025Accounts Payable
1.18MUSDFY2025 · Dec 31, 2025Short-term Debt
472.00KUSDFY2025 · Dec 31, 2025Long-term Debt
5.34MUSDFY2025 · Dec 31, 2025Common Stock (Book)
0.00USDFY2025 · Dec 31, 2025Retained Earnings
-371.26MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
259.18MUSDvs all stocks (USD)
52-Week Low
9.96USDUpdated Jul 19, 202652-Week High
40.65USDUpdated Jul 19, 202652-Week Change
202.83%vs all stocks
Beta
0.7640xvs all stocks
50-Day MA
31.35USDUpdated Jul 19, 2026200-Day MA
27.99USDUpdated Jul 19, 2026Avg 10-Day Volume
614.78KSharesUpdated Jul 19, 2026Avg 30-Day Volume
992.34KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-2.18USDUpdated Jul 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.69
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Market cap is $1.91B, above the global median of $1.15BNotable
Market cap (USD): 1,910,783,341Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Fagron NV
Tier 1ProductionApproval-Gated PipelineFlowRule
Galapagos NV
Tier 1ProductionApproval-Gated PipelineRuleRisk
Amylyx Pharmaceuticals, Inc. Common Stock
Tier 1ProductionApproval-Gated PipelineRule
Beijing Aosaikang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hugel Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Damora Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
AbCellera Biologics Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Nanjing Vazyme Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
UFP Technologies Inc.
Tier 1ProductionApproval-Gated PipelineRule